Drugs / Modi-1 Moditope
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05329532 | Apr 2022 → Jul 2026 overdue | head and neck squamous cell carcinoma, ovarian serous adenocarcinoma, renal cell carcinoma, triple-negative breast carcinoma | Scancell Ltd | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-01-09 | Scancell Ltd | Results Scancell’s Modi-1 Moditope Vaccine Achieves Early Clinical Validation in Head and Neck Cancer scancell.co.uk ↗
Three of the seven evaluable patients that have received immunisation with Modi -1 Moditope® combined with a checkpoint inhibitor have demonstrated a partial response as determined by RECIST 1.1 tumour assessment at their 25-week scan. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-01-09 | Scancell Ltd | Scancell’s Modi-1 Moditope Vaccine Achieves Early Clinical Validation in Head and Neck Cancer scancell.co.uk ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Modi-1 Moditope | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05329532 ↗ |
| Modality | Vaccine | “Modi-1 Moditope vaccine” NCT05329532 ↗ |